Acute kidney injury is associated with severe and fatal outcomes in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies

Mohammad Parohan, Sajad Yaghoubi, Mahmoud Djalali, Asal Seraji, Mohammad Hassan Javanbakht, Zahra Mousavi
doi: https://doi.org/10.1101/2020.08.27.20183632

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic impacting 213 countries and territories with more than 17,918,582 cases worldwide. Kidney dysfunction has been reported to occur in severe and death cases. This meta-analysis was done to summarize available studies on the association between acute kidney injury and severity of COVID-19 infection. Online databases including Web of Science, PubMed/Medline, Cochrane Library, Scopus and Google Scholar were searched to detect relevant articles up to 1 July 2020, using relevant keywords. To pool data, a random- or fixed-effects model was used based on the heterogeneity between studies. In total, 50 studies with 8,180 COVID-19 confirmed cases (severe cases=1,823 and death cases=775), were included in this meta-analysis. Higher serum levels of creatinine (weighted mean difference (WMD) for disease severity=5.47 μmol/L, 95% CI=2.89 to 8.05, P<0.001 and WMD for mortality=18.32 μmol/L, 95% CI=12.88 to 23.75, P<0.001), blood urea nitrogen (BUN) (WMD for disease severity=1.10 mmol/L, 95% CI=0.67 to 1.54, P<0.001 and WMD for mortality=3.56 mmol/L, 95% CI=2.65 to 4.48, P<0.001) and lower levels of estimated glomerular filtration rate (eGFR) (WMD for disease severity=-15.34 mL/min/1.73 m2, 95% CI=-18.46 to -12.22, P<0.001 and WMD for mortality=-22.74 mL/min/1.73 m2, 95% CI=-27.18 to -18.31, P<0.001) were associated with a significant increase in the severity and mortality of COVID-19 infection. Acute kidney injury, as assessed by kidney biomarkers (serum creatinine, BUN and eGFR), was associated with severe outcome and death from COVID-19 infection.

Introduction

Coronavirus disease 2019 (COVID-19) is a global pandemic impacting 213 countries, areas and territories with a total of 17,918,582 confirmed cases and 686,703 deaths worldwide 1. As the COVID-19 outbreak expands, identification of clinical and laboratory predictors for severe and fatal outcomes are essential to enable risk stratification, guide public health recommendations and optimize allocation of limited hospital resources in the ongoing pandemic.

Genome sequencing showed that the COVID-19 belongs to β genus of Coronavirus, which also includes Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) 2. Similar to SARS, COVID-19 infection is caused by binding of the virus to the angiotensin-converting enzyme 2 (ACE2) receptors 3. ACE2 receptors are highly expressed in the lungs, kidneys, heart, vascular endothelium, liver and intestinal epithelium, providing a mechanism for the multi-organ dysfunction that can be seen with COVID-19 infection 4, 5.

Multiple observational studies have reported the clinical features and laboratory findings associated with acute kidney injury in patients with COVID-19 infection 6-55. In this study, the laboratory findings and mechanism of kidney dysfunction caused by COVID-19 were summarized.

Methods

Study protocol

A systematic literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 56.

Search strategy

We conducted a systematic search using the online databases of Web of Science, PubMed/Medline, Cochrane Library, Scopus and Google Scholar for relevant articles up to 1 July 2020. The following medical subject headings (MeSH) and non-MeSH terms were used: (“Novel Coronavirus” OR “2019‐nCoV” OR “Coronavirus disease 2019” OR “COVID-19” OR “Severe acute respiratory syndrome Coronavirus 2” OR “SARS-CoV-2”) AND (“estimated Glomerular filtration rate” OR “eGFR” OR “Creatinine clearance” OR “Blood Urea Nitrogen” OR “BUN” OR “Creatinine” OR “Kidney diseases” OR “Acute Kidney injury”). The systematic search was done by two reviewers (MP and SY). The reference lists of the relevant articles were also searched to identify missed studies. No restriction was applied to publication year and language. The search results were downloaded into an EndNote library (version X8, Thomson Reuters, Philadelphia, USA) and titles/abstracts assessed for eligibility. The keywords and search strategies are presented in Supplementary Table 1.

Eligibility Criteria

Studies were included in this systematic review and meta-analysis if they met the following inclusion criteria: (1) observational studies (either retrospective or prospective); (2) studies assessing the association between kidney biomarkers (including eGFR, BUN and serum creatinine) and severe outcome or death from COVID-19 infection and reported mean (SD) or median (IQR) for these biomarkers. Reviews, expert opinion articles, books and theses were excluded.

Data extraction and assessment for study quality

Two reviewers (MP and AS) extracted the following data from the included articles: publication year, author’s name, study design, demographic characteristics including age and gender, sample size, outcome assessment methods and kidney biomarkers including eGFR, BUN and creatinine.

The Newcastle-Ottawa Scale was used for assessing the quality and risk of bias of included articles 57. Based on this criteria, a maximum of nine points can be awarded to each article. In this meta-analysis, articles with the Newcastle–Ottawa Scale score of ≥ 5 were considered as high quality studies.

Statistical analysis

Mean (SD) or median (IQR) for eGFR, BUN and serum creatinine were used to estimate the effect size. The fixed or random-effect model was performed depending on the heterogeneity between studies. Heterogeneity between studies was assessed using the Cochrane Q test and I2 statistics 58. The publication bias was assessed by the Egger’s regression test 59.The sensitivity analysis was used to evaluate the effect of each study on the pooled effect size. Statistical analyses were performed using the Stata 14 software package (Stata Corp, College Station, TX, USA).

Results

Search results

Overall, 623 articles were identified in our systematic literature search. Of these, 41 non-English, 215 duplicates, 83 reviews and 223 articles that did not fulfill our inclusion criteria were excluded, leaving 61 publications for further evaluation. Out of remaining 61 papers, 11 were excluded because of the following reason: did not report mean (SD) or median (IQR) for kidney biomarkers. Finally, we included 50 articles in this meta-analysis (Figure 1).

Fig. 1
Fig. 1

Flow chart of study selection

Study characteristics

Forty-six studies were conducted in China 6-17, 19, 20, 22-28, 30-34, 36-43, 45-55, 60, one in United States 29, one in United Kingdom44, one in Japan35 and one in Italy21. Forty-seven studies used retrospective design 6, 7, 9-15, 17, 19, 20, 22-55, 60 and three studies used prospective design 8, 16, 21. The mean age in severe and non-severe patients were 64.4 and 52.1 years, respectively. The sample size of studies ranged from 10 to 671 participants. All studies used real-time reverse transcriptase–polymerase chain reaction (RT-PCR) method to confirm COVID-19 infection. The characteristics of the studies are presented in Table 1.

View this table:
Table 1.

Characteristics of studies included in the meta-analysis.

Serum levels of creatinine, BUN, eGFR and severity of COVID-19 infection

In the pooled estimate of 36 studies 6, 8-15, 17, 19, 21-24, 26-35, 37-40, 46, 49, 51, 53-55, 60 with 5,104 COVID-19 confirmed patients (severe cases = 1,796 and non-severe cases = 3,308), it was shown that higher serum levels of creatinine (weighted mean difference = 5.47 μmol/L, 95% CI = 2.89 to 8.05, P<0.001, I2 = 64.5%, Pheterogeneity <0.001) (Figure 2) and BUN (weighted mean difference = 1.10 mmol/L, 95% CI = 0.67 to 1.54, P<0.001, I2 = 77.3%, Pheterogeneity <0.001) (Figure 3), were associated with a significant increase in the severity of COVID-19 infection. In addition, combined results from the fixed-effects model showed that lower levels of eGFR (weighted mean difference = -15.34 mL/min/1.73 m2, 95% CI = -18.46 to -12.22, P<0.001, I2 = 0.0%, Pheterogeneity = 0.689) (Figure 4), significantly increased severity of the disease.

Fig. 2
Fig. 2

Forest plot for the association between serum levels of creatinine and severe outcome from COVID-19 infection using random-effects model

Fig. 3
Fig. 3

Forest plot for the association between BUN levels and severe outcome or death from COVID-19 infection using random-effects model

Fig. 4
Fig. 4

Forest plot for the association between levels of eGFR and severe outcome or death from COVID-19 infection using fixed-effects model

Serum levels of creatinine, BUN, eGFR and mortality from COVID-19 infection

Fifteen studies 7, 13, 16, 20, 25, 36, 41-45, 47, 48, 50, 52 including a total of 3,080 COVID-19 infected patients (non-survivor = 775 and survivor = 2,305) reported mortality as an outcome measure. Pooled analysis showed that higher serum levels of creatinine (weighted mean difference = 18.32 μmol/L, 95% CI = 12.88 to 23.75, P<0.001, I2 = 64.1%, Pheterogeneity <0.001) (Figure 5), BUN (weighted mean difference = 3.56 mmol/L, 95% CI = 2.65 to 4.48, P<0.001, I2 = 72.4%, Pheterogeneity = 0.001) (Figure 3) and lower levels of eGFR (weighted mean difference = -22.74 mL/min/1.73 m2, 95% CI = -27.18 to -18.31, P<0.001, I2 = 43.2%, Pheterogeneity = 0.153) (Figure 4), were associated with a significant increase in the mortality of COVID-19 infection.

Fig. 5
Fig. 5

Forest plot for the association between serum levels of creatinine and mortality from COVID-19 infection using random-effects model

Publication bias and sensitivity analysis

Based on the visual inspection of funnel plot and the results of Egger’s regression test, we found no evidence of publication bias for creatinine (P=0.924) (Supplementary Figure 1) and eGFR (P=0.612) (Supplementary Figure 2). Based on Egger's regression test, publication bias existed for BUN (P=0.024) (Supplementary Figure 3), and we used meta-trim method to re-estimate the effect size. The adjusted weighted mean difference after the trim and fill analysis was 0.73 (95% CI: 0.26 – 1.19, P = 0.002) in the random-effects model. In addition, findings from sensitivity analysis revealed that overall estimates did not depend on a single study.

Discussion

Findings from this meta-analysis showed that kidney dysfunction is associated with severe outcome and death from COVID-19 infection. To our best knowledge, this study is the first meta-analysis to assess the association between kidney biomarkers, in particular eGFR and severity of COVID-19 infection.

The findings from our study are in agreement with previous reviews 61-64. Previously, kidney injury has been reported as a significant risk factor for severe outcome and death in SARS and MERS 65, 66.

COVID-19 may either exacerbate preexisting chronic kidney diseases and/or induce new acute kidney injuries. Earlier studies have shown that the incidence of acute kidney injury in severe COVID-19 patients and death cases ranged from 3.7% to 70.7% and 18.3% to 73.7%, respectively 10, 25, 37, 45.

The pathophysiology of COVID-19 associated acute kidney injury could be related to specific and nonspecific mechanisms. Specific mechanisms include direct cellular injury resulting from viral entry through the angiotensin-converting enzyme 2 receptor which is highly expressed in the kidneys 3, 67, an imbalanced renin–angiotensin–aldosterone system activation, leading to vasoconstriction, inflammation and fibrosis 68, 69, cytokine storm, mediated by increased pro-inflammatory cytokine production after COVID-19 infection 61 and thrombotic events 70. Nonspecific mechanisms include hypovolemia 8, right heart failure, hemodynamic changes such as central venous pressure elevation and increased intra-thoracic pressure 71, high levels of positive end-expiratory pressure in patients requiring mechanical ventilation 72, 73, nosocomial sepsis and administration of nephrotoxic drugs, especially antibiotics, antiviral therapy and/or traditional medicine 61.

Furthermore, increased fraction of inspired oxygen (FiO2) requirement and respiratory failure can also contribute to renal hypoperfusion and medullary hypoxia resulting from combined effects of third-space fluid loss, endothelial damage and hypotension from COVID-19-induced cytokine release 74.

Urine sediments of COVID-19 infected patients showed subnephrotic microhematuria and proteinuria, which are consistent with autopsy findings of kidney tissues of these patients showing proximal tubule injury with erythrocyte aggregates obstructing the peritubular capillaries and tubular necrosis with macrophage infiltration 70.

Until effective therapies against COVID-19 become available, the treatment of disease will be primarily based on the treatment of complications. Treatment of kidney complications should be based on optimal use of guideline-based therapies.

This study has some limitations. First, interpretation of results might be limited by the low sample size. Second, the present study did not include data such as smoking history and body mass index and, which are potential risk factors for disease severity.

Conclusion

In this meta-analysis of 8,180 COVID-19 infected patients, acute kidney injury as assessed by serum levels of creatinine, BUN and eGFR was associated with severe outcome and death from COVID-19 infection.

Data Availability

All data are publicly available.

DECLARATION OF INTEREST

The authors report no conflict of interest.

FUNDING

None.

Supporting Information

Supplementary table 1. Systematic literature review search terms and strategy.

Supplementary Figure 1. Funnel plot for the association between serum levels of creatinine and severity of COVID-19 infection.

Supplementary Figure 2. Funnel plot for the association between eGFR and severity of COVID-19 infection.

Supplementary Figure 3. Funnel plot for the association between BUN levels and severity of COVID-19 infection.

ACKNOWLEDGEMENT

None.

References

  1. 1.↵
    World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-196. August 3, 2020.
  2. 2.↵
    Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80.e8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012;2012:256294.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020.
  7. 7.↵
    Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020.
  10. 10.↵
    Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020.
  11. 11.
    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.
  12. 12.
    Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.
  13. 13.↵
    Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020.
  14. 14.
    Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020.
  15. 15.↵
    Du RH, Liu LM, Yin W, Wang W, Guan LL, Yuan ML, et al. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. Ann Am Thorac Soc. 2020.
  16. 16.↵
    Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur Respir J. 2020.
  17. 17.↵
    Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16(10):1698–707.
    OpenUrlCrossRef
  18. 18.
    Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020.
  19. 19.↵
    Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404–10.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.
  21. 21.↵
    Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Cao Z, Li T, Liang L, Wang H, Wei F, Meng S, et al. Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One. 2020;15(6):e0234764.
    OpenUrl
  23. 23.
    Chen C, Wang H, Liang Z, Peng L, Zhao F, Yang L, et al. Predicting Illness Severity and Short-Term Outcomes of COVID-19: A Retrospective Cohort Study in China. The Innovation. 2020;1(1).
  24. 24.↵
    Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020:1-9.
  25. 25.↵
    Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–7.
    OpenUrlCrossRef
  26. 26.↵
    Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380–8.
    OpenUrlCrossRefPubMed
  27. 27.
    Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791–6.
    OpenUrl
  28. 28.↵
    Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19): A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 2020.
  29. 29.↵
    Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–4.
    OpenUrlPubMed
  30. 30.↵
    Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int. 2020;40(6):1321–6.
    OpenUrlCrossRefPubMed
  31. 31.
    Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. Yonsei Med J. 2020;61(5):431–7.
    OpenUrlPubMed
  32. 32.
    Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond). 2020;52(7):498–505.
    OpenUrl
  33. 33.
    Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis. 2020;14(5):e0008280.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Jin A, Yan B, Hua W, Feng D, Xu B, Liang L, et al. Clinical characteristics of patients diagnosed with COVID-19 in Beijing. Biosafety and Health. 2020.
  35. 35.↵
    Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K, Nagamine K, et al. Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship. J Infect Chemother. 2020;26(8):865–9.
    OpenUrl
  36. 36.↵
    Li D, Chen Y, Liu H, Jia Y, Li F, Wang W, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study. Signal Transduct Target Ther. 2020;5(1):62.
    OpenUrl
  37. 37.↵
    Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794–800.
    OpenUrlPubMed
  38. 38.
    Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032–8.
    OpenUrl
  39. 39.
    Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157–65.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM. 2020.
  41. 41.↵
    Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care. 2020;43(7):1382–91.
    OpenUrlAbstract/FREE Full Text
  42. 42.
    Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070–9.
    OpenUrlPubMed
  43. 43.↵
    Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study. J Am Geriatr Soc. 2020;68(6):E19-e23.
    OpenUrlPubMed
  44. 44.↵
    Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect. 2020.
  45. 45.↵
    Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020;24(1):188.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA. Endocr Pract. 2020;26(6):668–74.
    OpenUrl
  47. 47.↵
    Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clin Infect Dis. 2020.
  48. 48.↵
    Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639–45.
    OpenUrlCrossRefPubMed
  49. 49.↵
    Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020;288(1):128–38.
    OpenUrlCrossRef
  50. 50.↵
    Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1).
  51. 51.↵
    Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020.
  52. 52.↵
    Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.
    OpenUrlPubMed
  53. 53.↵
    Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clin Ther. 2020;42(6):964–72.
    OpenUrl
  54. 54.
    Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364.
    OpenUrlCrossRefPubMed
  55. 55.↵
    Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020.
  56. 56.↵
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    Jiang Y, He S, Zhang C, Wang X, Chen X, Jin Y, et al. Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China. Ann Transl Med. 2020;8(8):547.
    OpenUrl
  61. 61.↵
    Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020:1-10.
  62. 62.
    Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020;24(1):346.
    OpenUrlPubMed
  63. 63.
    Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020;42(1):393–7.
    OpenUrlCrossRefPubMed
  64. 64.↵
    Fanelli V, Fiorentino M, Cantaluppi V, Gesualdo L, Stallone G, Ronco C, et al. Acute kidney injury in SARS-CoV-2 infected patients. Crit Care. 2020;24(1):155.
    OpenUrlCrossRefPubMed
  65. 65.↵
    Rong Y, Chang W, Liu Y, Xuemei M, Chang B, Yang Y, et al. Damage to non-pulmonary organs like heart and kidney in SARS patients: An analysis of 330 cases. Academic Journal of Second Military Medical University. 2000(08).
  66. 66.↵
    Yeung M-L, Yao Y, Jia L, Chan JF, Chan K-H, Cheung K-F, et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nature microbiology. 2016;1(3):1–8.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Pan X-w, Da Xu HZ, Zhou W, Wang L-h, Cui X-g. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020:1.
  68. 68.↵
    Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin– angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.
    OpenUrlCrossRefPubMed
  69. 69.↵
    Malha L, Mueller FB, Pecker MS, Mann SJ, August P, Feig PU. COVID-19 and the Renin-Angiotensin System. Kidney Int Rep. 2020;5(5):563–5.
    OpenUrl
  70. 70.↵
    Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–27.
    OpenUrlCrossRefPubMed
  71. 71.↵
    Joannidis M, Forni LG, Klein SJ, Honore PM, Kashani K, Ostermann M, et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med. 2020;46(4):654–72.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer S, Edwards V, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA. 2003;289(16):2104–12.
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    Ranieri VM, Giunta F, Suter PM, Slutsky AS. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA. 2000;284(1):43–4.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308–10.
    OpenUrlPubMed
Back to top
Posted September 01, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Acute kidney injury is associated with severe and fatal outcomes in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies
Mohammad Parohan, Sajad Yaghoubi, Mahmoud Djalali, Asal Seraji, Mohammad Hassan Javanbakht, Zahra Mousavi
medRxiv 2020.08.27.20183632; doi: https://doi.org/10.1101/2020.08.27.20183632
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area